Operator Tips, Volume 4: We Built the Cannabis Industry. Did We Forget Why?

Cannabis conferences are packed with conversations about capital, consolidation, AI, regulation, retail, and survival. Those conversations matter. But the patients, medicine, and plant that helped build this industry are increasingly harder to find on the agenda.

I was scrolling through the agendas for National Cannabis Conferences when something occurred to me.

Capital. Consolidation. Artificial intelligence. Retail data. Branding. Customer acquisition. Regulation. Price compression. Policy.

All important conversations. All necessary conversations, especially in a market where License holders are fighting to survive. But the farther I scrolled, the more obvious the question became: Where was the medicine?

Not cannabis the market. Not cannabis the asset class. Not cannabis the SKU. Not cannabis the regulatory problem. Cannabis the plant. Cannabis the medicine. Cannabis and the people whose lives it has changed.

That question has stayed with me because it says something bigger about where this industry is headed.

The Cannabis Industry Grew Up, and the Conversation Changed

I spend a lot of time at cannabis conferences. I attend them, learn from them, network at them, and have built lasting relationships through them. I believe they matter.

This industry needs rooms where operators, regulators, investors, cultivators, researchers, advocates, service providers, and entrepreneurs can talk honestly about what is working and what is not.

Right now, operators need help. Margins are compressed. Capital is difficult. Regulations are expensive. Competition is brutal. Taxes are punishing.

I understand why conference agendas are filled with M&A, compliance, retail analytics, banking, AI, branding, and operational efficiency.

I make my living helping cannabis operators plan for risk. Businesses that do not survive cannot serve anyone. But I did not come to cannabis because it was an industry. The plant came first.

Long before I ever thought about cannabis as a market I wanted to help insure, I understood it as something people connected with, relied on, and believed in.

The modern legal movement was pushed forward by patients, caregivers, parents, veterans, advocates, cultivators, and people willing to challenge decades of stigma because their lived experiences did not match what they had been told.

Somewhere between movement and market, our vocabulary changed.

A Medical Market Is Not the Same as Cannabis Medicine

An upcoming Colorado Cannabis conference made that change easy to see.

On the published schedule, I counted 19 named independent sessions. Only one explicitly centered medical cannabis. None of the 19 session titles explicitly centered patient care, therapeutic use, dosing, cannabinoids, terpenes, the endocannabinoid system, or whole plant medicine.

Instead, the agenda focused heavily on capital, consolidation, AI, retail, customer acquisition, and business survival.

Those are useful topics. My point is not that they should disappear.

My point is what is missing beside them: the conversations that remind us why this plant mattered enough for people to fight for access in the first place. There is a difference between talking about the medical cannabis market and talking about cannabis medicine.

That distinction gets even clearer when the conversation turns toward questions such as who becomes investable, who gets access to emerging markets, and who gets paid.

Those are legitimate business questions. But “Who gets paid?” is not the same question as “Who gets better?”

Operator Tip: A medical cannabis market and cannabis medicine are not the same conversation. One asks how businesses participate. The other asks how cannabis affects human beings. We need both.